Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accessibility, ADCC, ADCP, adenosine, Adimab, afucosylated, aggressive, agreeable, ahead, antigen, appraisal, bankrupt, bargain, Bayer, Biomedical, brochure, calendar, casdozokitug, cellular, chemokine, chosen, CIRT, Citigroup, Clawback, cloud, cluster, companion, compulsory, Computershare, consummated, consummation, content, correlated, Crimson, Cuban, cultivated, CVR, cytolytic, cytotoxicity, Dec, deceptive, depletion, diagnosed, diagnostic, differentiation, disaggregation, distant, divestiture, DPF, DRG, East, elicit, enterprise, enzyme, evidenced, explained, exploit, extracellular, FDIC, forma, France, garnering, Germany, GSK, HCC, hepatocellular, hybrid, immunological, Immunophage, immunosuppressive, inhibitory, Insider, interdisciplinary, interleukin, irrevocable, isotype, Italy, jeopardize, killer, LaNova, Lee, locoregionally, longevity, LOQTORZI, lucrative, mail, makewhole, McMichael, median, memory, metabolite, middle, Morgan, nationwide, NCCN, Neck, Newcomer, NIST, NK, nontransferable, nose, ONBODY, OS, overexpressed, PBC, pension, perpetual, physiologic, placenta, pregnancy, proper, proximity, purport, purpose, PVRIG, qualitative, quantitative, radiation, reaction, regain, reinsurance, residual, restraining, retroactive, retrospective, retrospectively, revert, revised, SCCHN, SEER, Shionogi, Silicon, skull, Spain, speed, split, surgery, suspected, TD, text, throat, tighter, Treg, unaudited, uncured, undisputed, upper, uptake, vaccinated, Vaccinex, Valley, Vice, WAC, yearly
Removed:
AB, Absent, Arzneimittel, ASC, Avastin, Bausch, bevacizumab, binomial, Biogen, Breakthrough, collaborator, comparability, comprised, computation, consecutive, contracting, correction, depression, earn, engineering, fifty, governor, hoping, humanized, infliximab, initiating, Innovent, lattice, Lomb, maturing, NASH, Pharma, PPAR, preponderance, qualification, qualifying, quarantining, recession, redeemed, redemption, regime, Remicade, requested, rolling, server, Shield, showed, simplified, spam, spread, STADA, straight, strained, subjectively, successive, Suzhou, thirty, widespread, Xbrane
Financial report summary
?Competition
Baxter International • Bristol-Myers Squibb • Fresenius Medical Care • Mylan • Pfizer • Spectrum Pharmaceuticals • Regeneron Pharmaceuticals • Biogen • Astrazeneca • SanofiManagement Discussion
- The increase in net revenue was primarily due to our three new products: CIMERLI launched in October 2022 and contributed $118.4 million more in 2023 as compared to 2022, YUSIMRY launched in July 2023 contributing $3.6 million, and LOQTORZI sales to distributors began in December ahead of the January 2024 launch, contributing $0.6 million of net revenue. This was partially offset by a $76.8 million decline in UDENYCA net revenue as compared to 2022, primarily related to the decline in the average net selling price per unit. Our net revenue and market penetration may continue to be adversely impacted by pricing trends and competitive dynamics in the overall pegfilgrastim market. In addition, the COVID-19 pandemic has negatively impacted the pre-filled syringe pegfilgrastim market due to preferences to administer medication at home.